8,864 reports of this reaction
8.8% of all CONJUGATED ESTROGENS reports
#2 most reported adverse reaction
BREAST CANCER FEMALE is the #2 most commonly reported adverse reaction for CONJUGATED ESTROGENS, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 8,864 FDA adverse event reports linking CONJUGATED ESTROGENS to BREAST CANCER FEMALE. This represents approximately 8.8% of all 100,524 adverse event reports for this drug.
Patients taking CONJUGATED ESTROGENS who experience breast cancer female should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER FEMALE is moderately reported among CONJUGATED ESTROGENS users, representing a notable but not dominant share of adverse events.
In addition to breast cancer female, the following adverse reactions have been reported for CONJUGATED ESTROGENS:
The following drugs have also been linked to breast cancer female in FDA adverse event reports:
BREAST CANCER FEMALE has been reported as an adverse event in 8,864 FDA reports for CONJUGATED ESTROGENS. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER FEMALE accounts for approximately 8.8% of all adverse event reports for CONJUGATED ESTROGENS, making it one of the most commonly reported side effect.
If you experience breast cancer female while taking CONJUGATED ESTROGENS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.